In the forefront of the battle against emerging infectious diseases

Avraham Shimon Marilus CEODorit Arad CSO and Founder

Mission

Be ready to

Rapidly detectPrevent the spreadProvide better treatment

for infectious diseases particularly those that impose

world pandemics threat

MND’s Platform

Novel (Based on viral enzyme detection)

Rapid (only 3 minutes detection)Detection of live viruses

For pandemic causing viruses to prevent

their spread

For existing viruses to

provide a better care

MND diagnostics

• Founded in2004 as an incubator company

• Established a collaboration with BMD (Biomedical Diagnostic, France)

• Recently completed first round of $4.7 million financing from Swiss investors

• Achieved proof of concept on the detection of enterovirus meningitis in CSF samples

Manpower: 10 persons.

Situated in Science Park Nes-Ziona.

Business Development The BDC Group

Prof Max Herzberg Prof. Christian Policard Ms. Nicole Rieunier-Burle

Clinical StudiesClinical StudiesDavid Greenberg M.D., David Greenberg M.D., Medical director, SorokaMedical director, SorokaHospital, Israel. Hospital, Israel. Prof. Dana Wolf, Hadassah Prof. Dana Wolf, Hadassah

Hospital, IsraelHospital, Israel

Mr. AvrahamMr. Avraham Marilus CEO and Chairman Marilus CEO and Chairman Dr. Dorit Arad – CSO and founderDr. Dorit Arad – CSO and founder

Dr. Ouriel Faktor VP R&DDr. Ouriel Faktor VP R&DProf. Max Herzberg - DirectorProf. Max Herzberg - Director

The MND Team

Development TeamDevelopment Team

Yaniv Nevo Ph.DYaniv Nevo Ph.D

Assaf Ezra Assaf Ezra

Ofer Nusbaum Ph.D Ofer Nusbaum Ph.D

Gilad WainrebGilad Wainreb

The Technology:Specific Enzymatic Based

assay

(I)

(II)

++

Peptide colorPeptide colorreactionreaction

viral enzymeviral enzyme

Quenched Quenched tag tag

SpecificSpecificsequencesequenceDetectorDetector

peptide peptide

(III)

Advantages

New IP – new niche in the crowded diagnostics arena Detecting virus in their active stage, unlike RT-PCR

and immunoassays Rapid detection relative to PCR (minutes relative to

hours) proprietary molecules Detection procedure is simple Inexpensive Could be adjusted to hand-held field usage (airports

and public places)

Business Model

MNDQPT

Technology

BMD Multiplex MeningitisPartner – Avian Flu (poultry)

MND single testMeningitis

Partner – emerging pandemic kitfor outbreak control

MND CMV

MND Avian Flu (Humans)

Combination of product development, licensing and partnering leverages MND’s IP and knowhow to its fullest

Current clinical Current clinical DevelopmentDevelopment

Meningitis Rapid Detection Kit

• The need for DetectionThe need for Detection• Each year in the United States 10 million to 15 million illnesses are

attributed to Enterovirus• 300,000 Lumbar Punctures are performed in the US every year. This

number will grow when there will be a fast detection tool to diagnose the disease.

• Current Gold Standard• The “gold standard” for Enterovirus detection is Tissue culture which

takes 3 days. RT-PCR takes 5-24 hours

• Current Development StatusCurrent Development Status• Proof of concept completed in 2007• Pre-clinical studies planned for Q3 2008• Over 100 clinical CSF samples tested successfully

Market Opportunities

1. Persistent viruses (Meningitis, Enterovirus, CMV and Rhinovirus)

2. Emerging viruses (Avian Flu, SARS).

Group A

CMV

Enteroviruses

Hepatitis A

Polio

Rhino Virus

Avian flu

Influenza A,B

SARS

Group B

Caliciviruses

EBV

Hepatitis C

Hepatitis E

Herpes A, B

West Nile

HIV

Group C

Adeno Virus

Para Influenza1,2,3Group D

RSV

12

IP & knowhow

Innovative MND’s intellectual property includes three pending patents on the detection method, compositions of matters for a wide range of viruses including HCV and detection of avian influenza.

KnowhowUnique molecular design techniques (QCT) enable the

creation of effective molecules, specific to each disease agent, for treatment and detection. Experience in the development of rapid testing formats

Creating leverage through MND’s novel IP

13

Company Goals 2008-2010

Launch Meningitis Rapid Detection Kit to market in 2009.

Advance MND platform and pipeline products for the detection of: Avian Influenza, CMV, HCV and Foot and Mouth disease.

Complete co-development of a Multiplex Detection Kit with BMD (BioMedical Diagnostics, France).

Establish strategic partnerships with leading Pharma.

Summary

MND technology has the potential to become a gold standard for Rapid detection, in non-lab conditions, of active infectious viruses such as: ENV, RHV, CMV, HCV, MFV, Inf.

MND broad technology can be expanded for development of Cancer markers and Blood coagulations diseases, and enrich the company pipeline.

MND relevant market segments - $13.3B (~34%) of the annual $40B IVD market.

We expect to launch our first product for meningitis detection in a year in third quarter of 2009.

Thank you!